Should I Buy ZBH? ZBH 2026 Analysis

Should You Buy Zimmer Biomet Holdings Inc (ZBH) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

85.520

1 Day change

-0.23%

52 Week Range

114.440

Analysis Updated At

2026/01/26

Zimmer Biomet Holdings Inc (ZBH) is not a strong buy for a beginner, long-term investor at this time. The stock is currently facing negative technical trends, weak analyst sentiment, and recent negative news catalysts. While the company has shown some revenue growth, declining net income and EPS, combined with the lack of significant positive trading signals, suggest holding off on investment until there is more clarity on its performance and outlook.

Technical Analysis

The technical indicators are bearish. The MACD is below zero and negatively contracting, the RSI is neutral at 31.824, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level of 86.291, with resistance at 92.521. The overall trend suggests weakness.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

The company's gross margin increased by 1.43% YoY in Q3 2025, and revenue grew by 9.71% YoY, indicating some operational improvements. Additionally, there is potential for a healthcare sector rebound in 2026, as noted by some analysts.

Neutral/Negative Catalysts

Zimmer Biomet is under investigation for potentially misleading revenue guidance, which has already caused a 15% stock drop. Analysts have downgraded the stock, citing inconsistent growth and challenges in revenue and earnings growth. The stock has a high likelihood of further short-term declines based on historical patterns. Insider and hedge fund trading trends are neutral, showing no significant support.

Financial Performance

In Q3 2025, revenue increased by 9.71% YoY to $2.001 billion. However, net income dropped by 7.31% YoY to $230.9 million, and EPS decreased by 5.69% YoY to $1.16. While gross margin improved to 63.24%, the decline in profitability metrics raises concerns about the company's operational efficiency.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is mixed to negative. Goldman Sachs downgraded the stock to Sell with a price target of $93, citing weak fundamentals. Raymond James downgraded it to Market Perform, citing inconsistent growth. While Evercore ISI upgraded the stock to Outperform with a price target of $120, most other analysts have lowered their price targets, with the average target hovering around $93-$100. This reflects cautious optimism but no strong consensus on significant upside potential.

18 Analyst Rating

Wall Street analysts forecast ZBH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZBH is 100.47 USD with a low forecast of 88 USD and a high forecast of 120 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

11 Hold

3 Sell

Hold

Current: 85.710

Low

Averages

100.47

High

120

Current: 85.710

Low

Averages

100.47

High

120

UBS

Sell -> Sell

downgrade

$88 -> $86

AI Analysis

2026-01-28

New

Reason

UBS

Price Target

$88 -> $86

AI Analysis

2026-01-28

New

downgrade

Sell -> Sell

Reason

UBS lowered the firm's price target on Zimmer Biomet to $86 from $88 and keeps a Sell rating on the shares.

TD Cowen

Mathew Blackman

Hold

Buy

upgrade

$99 -> $109

2026-01-26

New

Reason

TD Cowen

Mathew Blackman

Price Target

$99 -> $109

2026-01-26

New

upgrade

Hold

Buy

Reason

TD Cowen analyst Mathew Blackman upgraded Zimmer Biomet to Buy from Hold with a price target of $109, up from $99, as the analyst took over coverage of the stock. Despite what the analyst calls "very visible execution issues," the firm sees an improving growth and profit story with room for valuation to recalibrate higher, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ZBH

Unlock Now

ZBH Should I Buy

ZBH Should I Buy

Should You Buy Zimmer Biomet Holdings Inc (ZBH) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch